← Eichor
Study identifier: NCT06158412 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Condition: Multiple Myeloma in Relapse · Multiple Myeloma, Refractory  ·  Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 2
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

Zhijuan Lin, PhD  ·  +8615960283462  ·  zjuan_lin@126.com

Bing Xu, PhD  ·  +8618750918842  ·  xubingzhangjian@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Bing XuXiamen, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06158412